Research Services Portfolio – Transformative Insights from Discovery to Clinic
This comprehensive brochure provides an overview of our services offering.
This comprehensive brochure provides an overview of our services offering.
The brochure provides you with an overview of the key features and benefits of our next-generation TrueDiscovery™ platform. In addition, it elaborates on our deep and reproducible proteome, phospho- and immune-proteome quantification and analysis. Finally, it digs into how we identify the most promising and actionable biomarkers for research and clinical decision-making.
Learn more about Biognosys’ proprietary TrueTarget™ platform in our latest brochure. This resource elaborates on how TrueTarget™ identifies the most promising and actionable drug targets to support your research.
The brochure provides you with an overview of the key features and benefits of our next-generation TrueSignature™ platform. In addition, it elaborates on the specificities of our customizable panels for clinical and pharmacodynamics studies.
The case study provides you with an overview of the key features and benefits of our next-generation Plasma Biomarker Discovery solution. In addition, the case study elaborates on the results from our latest pan-cancer proteomics study.
The case study provides you with an overview of the key features and benefits of our next-generation Immunopeptidome Profiling solution. In addition, the case study elaborates on the results of our latest immunopeptidomics study on lung cancer.
We describe a first-of-its-kind study using multi-omics biomarker approaches to demonstrate pharmacodynamic effects and immune modulation in pancreatic cancer. Biognosys’ proprietary platform for unbiased proteomics, TrueDiscovery™, allowed the identification of pharmacodynamic markers and elucidated the mechanism of action of therapies under clinical investigation.
Harnessing the information present in the plasma proteome requires robust large-scale analytical techniques. Our latest white paper gives you a better understanding of two leading technology platforms for Plasma Proteomics: Biognosys’ TrueDiscovery™ and Olink Explore.
In this white paper, we explain how advances in mass spectrometry can now unlock the potential of the plasma proteome, uncovering actionable insights essential for biomarker discovery and targeted drug development.
In this white paper, you can learn about the key reasons why oncology drug development fails and how Biognosys’ proteomics platforms and applications can support your oncology research pipeline.
Biognosys AG
Wagistrasse 21
8952 Schlieren
Switzerland
Phone: +41 44 738 20 40
US Offices
Biognosys Inc
70 Bridge St, Suite 104
Newton, MA 02458
United States
